Mesoblast's clinical product pipeline derives from the Company’s proprietary Mesenchymal Cell Lineage technology platforms. Products using highly purified, immunoselected Mesenchymal Precursor Cells (MPCs) are being developed to generate sustained clinical outcomes following single-dose or intermittent administration locally or systemically. Products using Mesenchymal Stem Cells (MSCs) are being developed to induce rapid clinical responses following frequent repeat-dose administration systemically.
Mesoblast’s lead clinical product candidates focus on four major and distinct areas:
- systemic diseases with an underlying inflammatory and immunologic etiology where cells are administered intravenously to impart immunomodulatory effects
- cardiovascular diseases where cells are administered locally with the aim of improving heart anatomy and function
- orthopedic diseases of the spine where cells are locally administered to potentially repair intervertebral discs or generate new bone
- improving outcomes of bone marrow transplantation in patients with cancer or genetic diseases
The specific medical conditions targeted by Mesoblast’s lead products include acute graft versus host disease complicating bone marrow transplantation, Crohn’s disease and rheumatoid arthritis refractory to biologics, type 2 diabetes and kidney disease, congestive heart failure, acute myocardial infarction, and intervertebral disc diseases.